The Effect of Ropinirole on the Quality of Life in Patients with Restless Legs Syndrome in Korea: An 8-Week, Multicenter, Prospective Study
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background and Purpose Dopamine agonists are first-line drugs for treating the symptoms of restless legs syndrome (RLS). However, few studies have investigated the effect of dopamine agonists on the quality of life (QoL) in RLS patients. We conducted a study to determine whether ropinirole exerts positive effects on the QoL in RLS patients and to analyze the underlying factors. Methods Primary RLS patients from eight medical centers were recruited in the study. They were evaluated in the baseline phase using various questionnaires including the Korean versions of the International Restless Legs Scale (K-IRLS), RLS QoL questionnaire (K-RLSQoL),and the Short Form 36 Health Survey (SF-36). After taking ropinirole for 8 weeks the same questionnaires were again completed as a re-evaluation. We analyzed the statistical difference using a paired t-test, a Pearson’s correlation, and a stepwise multiple regression in order to identify the factors associated with the QoL change. Results A total of 107 subjects, including 65 (60.7%) females, completed this study. They were aged 51.68±14.80 years (mean±SD) and had a symptom duration of 8.8±9.0 months. After treatment with ropinirole, there were significant improvements on the K-RLSQoL, SF-36,and K-IRLS. The Pearson’s correlation analysis showed that the improvement of QoL in RLS patients was significantly correlated with the severity of RLS (r=0.236, p<0.014) at baseline. Conclusions The results from this study suggest that treatment with ropinirole can improve the QoL in RLS patients. The improvement in the QoL is more related with the improvement of RLS symptoms.
Abstract
Background and Purpose Dopamine agonists are first-line drugs for treating the symptoms of restless legs syndrome (RLS). However, few studies have investigated the effect of dopamine agonists on the quality of life (QoL) in RLS patients. We conducted a study to determine whether ropinirole exerts positive effects on the QoL in RLS patients and to analyze the underlying factors. Methods Primary RLS patients from eight medical centers were recruited in the study. They were evaluated in the baseline phase using various questionnaires including the Korean versions of the International Restless Legs Scale (K-IRLS), RLS QoL questionnaire (K-RLSQoL),and the Short Form 36 Health Survey (SF-36). After taking ropinirole for 8 weeks the same questionnaires were again completed as a re-evaluation. We analyzed the statistical difference using a paired t-test, a Pearson’s correlation, and a stepwise multiple regression in order to identify the factors associated with the QoL change. Results A total of 107 subjects, including 65 (60.7%) females, completed this study. They were aged 51.68±14.80 years (mean±SD) and had a symptom duration of 8.8±9.0 months. After treatment with ropinirole, there were significant improvements on the K-RLSQoL, SF-36,and K-IRLS. The Pearson’s correlation analysis showed that the improvement of QoL in RLS patients was significantly correlated with the severity of RLS (r=0.236, p<0.014) at baseline. Conclusions The results from this study suggest that treatment with ropinirole can improve the QoL in RLS patients. The improvement in the QoL is more related with the improvement of RLS symptoms.
참고문헌 (34)
- Allen RP, "Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health", Sleep Medicine, 4, pp.101~119 (2003)
- Earley CJ, "Restless legs syndrome: understanding its consequences and the need for better treatment", Sleep Medicine, 11, pp.807~815 (2010)
- Allen RP, "Restless legs syndrome prevalence and impact: REST general population study", Archives of Internal Medicine, 165, pp.1286~1292 (2005)
- Berger K, "Sex and the risk of restless legs syndrome in the general population", Archives of Internal Medicine, 164, pp.196~202 (2004)
- Bjorvatn B, "Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries", Sleep Medicine, 6, pp.307~312 (2005)
- Cho YW, "Epidemiology of restless legs syndrome in Korean adults", Sleep, 31, pp.219~223 (2008)
- Hening W, "Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study", Sleep Medicine, 5, pp.237~246 (2004)
- Högl B, "Restless legs syndrome: a community-based study of prevalence, severity, and risk factors", Neurology, 64, pp.1920~1924 (2005)
- Tison F, "Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study", Neurology, 65, pp.239~246 (2005)
- Allen RP, "Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome", The American Journal of Medicine, 120, pp.S13~S21 (2007)
- Abetz L, "Evaluating the quality of life of patients with restless legs syndrome", Clinical Therapeutics, 26, pp.925~935 (2004)
- Akpinar S, "Treatment of restless legs syndrome with levodopa plus benserazide", Archives of neurology, 39, pp.739~ (1982)
- Allen RP, "Augmentation of the restless legs syndrome with carbidopa", levodopa, 1996, pp.19, 205~213
- Trenkwalder C, "Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study", Neurology, 62, pp.1391~1397 (2004)
- Andersohn F, "Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists", Movement Disorders, 24, pp.129~133 (2009)
- Hornyak M, "Efficacy and safety of dopamine agonists in restless legs syndrome", Sleep Medicine, 13, pp.228~236 (2012)
- Cheer SM, "Ropinirole: for the treatment of restless legs syndrome", CNS Drugs, 18, pp.747~754 (2004)
- Trenkwalder C, "Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries", Journal of Neurology, Neurosurgery & Psychiatry, 75, pp.92~97 (2004)
- Walters AS, "Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study", Movement Disorders, 19, pp.1414~1423 (2004)
- Allen R, "Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome", Sleep, 27, pp.907~914 (2004)
- Bogan RK, "Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial", Mayo Clinic Proceedings, 81, pp.17~27 (2006)
- 조용원, "한국판 하지불안 증후군 역학 조사 설문과 존스홉킨스 전화 진단인터뷰 양식의 신뢰도 및 타당도 연구", 대한신경과학회지, 25(4), pp.494~499 (2007), 대한신경과학회
- 양준규, "한국판 국제하지불안척도와 하지불안증후군 삶의 질 설문지의 신뢰도 및 타당도 연구", 대한신경과학회지, 28(4), pp.263~269 (2010), 대한신경과학회
- Han CW, "Development of the Korean version of Short-Form 36-Item Health Survey: health related QOL of healthy elderly people and elderly patients in Korea", The Tohoku Journal of Experimental Medicine, 203, pp.189~194 (2004)
- Sohn SI, "The reliability and validity of the Korean version of the Pittsburgh Sleep Quality Index", Sleep and Breathing, 16, pp.803~812 (2012)
- Cho YW, "The reliability and validity of the Korean version of the Epworth sleepiness scale", Sleep and Breathing, 15, pp.377~384 (2011)
- Oh SM, "A study on the standardization of the hospital anxiety and depression scale for Koreans: a comparison of normal, depressed and anxious groups", 신경정신의학, 38, pp.289~296 (1999)
- Jo SA, "Usefulness of Beck Depression Inventory (BDI) in the Korean elderly population", International Journal of Geriatric Psychiatry, 22, pp.218~223 (2007)
- Kushida C, "Burden of restless legs syndrome on health-related quality of life", Quality of Life Research, 16, pp.617~624 (2007)
- Bogan RK, "Ropinirole treatment for restless legs syndrome", Expert Opinion on Pharmacotherapy, 9, pp.611~623 (2008)
- Picchietti D, "Restless legs syndrome, periodic limb movements in sleep, and depression", Sleep, 28, pp.891~898 (2005)
- Winkelman JW, "Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort", Sleep Medicine, 7, pp.545~552 (2006)
- Rottach KG, "Restless legs syndrome as side effect of second gen-eration antidepressants", Journal of Psychiatric Research, 43, pp.70~75 (2008)
- Benes H, "Ropinirole improves depressive symptoms and restless legs syn-drome severity in RLS patients: a multicentre, randomized, placebo-controlled study", Journal of Neurology, 258, pp.1046~1054 (2011)